Bio-Techne Corporation
corporate_fare Company Profile
Bio-Techne Corporation (NASDAQ:TECH) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for TECH at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-23, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 11 rated 8 or above. Recent SEC coverage for TECH spans 8-K, DEFA14A, 10-K, DEFM14A.
Recent high-impact activity:
- Shareholders Overwhelmingly Back Bio-Techne's $73/Share Sale to Merck KGaA
- Bio-Techne Shareholders Approve $73/Share Merck KGaA Acquisition
- Bio-Techne Supplements Proxy With Goldman Valuation Details Amid Shareholder Lawsuit
- Bio-Techne Discloses Shareholder Lawsuit Seeking to Block Merck Vote
- Bio-Techne FY2026 10-K: Flat Sales, 148% GAAP EPS Jump, and a $1B Wilson Wolf Obligation
Financial Snapshot
Short Interest & Short Volume
2.73 days to coverFINRA reported short interest of 7,703,626 shares in TECH as of the October 30, 2026 settlement, a 2.0% increase from the prior period — about 2.7 days to cover at its recent average daily volume. On November 20, 2026, 42.5% of TECH volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.